Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Naïve or treated chronic hepatitis B patients with positive HBsAg and negative HBeAg;~2. Quantitative serum HBsAg (qHBsAg) \<2000 IU/ml;~3. No HIV co-infection;~4. No obvious immunodeficiency (such as renal failure, chemotherapy, radiotherapy, immunosuppressant);~5. Aged 3 to 80 years;~Exclusion Criteria:~1. Pregnancy~2. Allergic to HBV vaccine or yeast.~3. Hepatic decompensation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Engerix-B (Type: EXPERIMENTAL): Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for \>20 years old and 20μg for \< or =20 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).